key: cord-0807447-v3rpbjy6
authors: Mardikar, Harshawardhan; Mardikar, Manjusha; Deshpande, Niteen; Deshpande, Mohan; Admane, Parag
title: COVID-19 Second Wave in India – Wait or Act?
date: 2021-06-25
journal: Am J Med
DOI: 10.1016/j.amjmed.2021.06.002
sha: 87bcb85b2221a8002b724e79a487da560ae8dd69
doc_id: 807447
cord_uid: v3rpbjy6

nan

In the middle of January, many Indians and the government started to think that the COVID-19 pandemic was receding. The situation took a turn for the worse in March. For those needing admission to hospital, the injection remdesivir is the only treatment approved by the US Food and Drug Administration (FDA) for COVID-19 requiring admission. 1 While contemporary guidance from various government organizations recommend admission and injectable therapies for COVID-19 patients, this approach is contingent on the availability of beds. Shortages of hospital beds have prompted an urgent need to provide outpatient care. We treated a small group of moderate risk patients waiting for admission using an outpatient strategy. To the best of our knowledge, no outpatient strategy has been studied in this group. Moderate risk was defined using biomarkers & radiographic study. 2 & 3 We treated 15 moderate risk patients above the age of 60 years. All had evidence of lower respiratory tract involvement on computed tomography (CT) with oxygen saturation ≥ 94% and at least one comorbidity. All patients had fever of less than 72 hours duration. We studied two biomarkers for enrolment: C-reactive protein (CRP) and D-dimer. When at least one biomarker was elevated along with a positive reverse transcription polymerase chain reaction (RT-PCR) test, the patient was given intravenous remdesivir on an outpatient basis with a starting dose of 200 mg Intra Venous (IV) over 1 hour followed by 100 mg/day IV for 4 days. All patients were observed in the outpatient department for 1 hour post injection. Biomarker measurements were repeated on completion of therapy. Patients were encouraged to seek admission to the hospital for further treatment or in case of a drop in oxygen saturation. However, due to the lack of a centralized system of admission and some reluctance from patients and relatives, only three were admitted, two in a stable state and one as an emergency due to hypoglycemia.

Irrespective of age and comorbidities, all patients showed a very good response at the end of therapy with no fever, restored appetite and improvement in oxygen saturation as compared to baseline. The biomarkers stabilized in most patients and no patient required emergency admission to the hospital for mechanical ventilation.

Our approach suggests that outpatient treatment is feasible and setting up day care center can help preserve beds for seriously ill and also save costs.

Declaration of Competing Interest None Funding None

FDA Approval of Remdesivir -A Step in the Right Direction

Multiple Biomarker Approach to Risk Stratification in COVID-19

Mild or Moderate Covid-19